Eli Lilly and Co.

Sue Mahony, currently Lilly’s senior vice president of human resources and diversity, has been named senior vice president and president of Lilly Oncology. She will continue to report to Lilly’s chief executive officer, John Lechleiter, Ph.D., and she remains a member of the company’s executive committee. Ms. Mahony succeeds John H. Johnson, who recently resigned.

Steve Fry will take over for Ms. Mahony as senior vice president of HR and diversity. He previously served as vice president of HR for Lilly’s bio-medicines and emerging markets. Mr. Fry joins Lilly’s executive leadership team and reports to Dr. Lechleiter.

“Sue brings a deep understanding of both the scientific and commercial aspects of our business gained through a broad range of leadership roles here at Lilly and with other major pharmaceutical companies,” said Dr. Lechleiter. “Steve is a human resources professional who has also played a critical role in shaping our organizational approach, including the new business areas we formed last year. His varied experiences give him a firm grasp of how our business operates in all parts of the world.”

Ms. Mahony joined the company more than 10 years ago after having held positions with Amgen, Bristol-Myers Squibb, and Schering-Plough in sales and marketing roles in the UK and Europe in oncology/hematology and cardiovascular medicine. She served as general manager of Lilly Canada in 2008 after roles in global marketing and new product development, and was promoted to the top HR role in 2009.

Mr. Fry’s previous roles at Lilly include serving as managing director of Lilly’s Australian affiliate from 2004 – 2007, then in human resources capacities as executive director for the intercontinental region and Japan, and later becoming vice president for bio-medicines and emerging markets. He joined the company in 1987 as a scientific systems analyst at Lilly’s former Greenfield, IN laboratories and moved into HR in 1992.